Bafetinib
Bafetinib
Bafetinib (pronounced: ba-fe-ti-nib) is a type of protein kinase inhibitor used in the treatment of various types of cancer. It is a second-generation tyrosine kinase inhibitor that is designed to overcome resistance to treatment.
Etymology
The term "Bafetinib" is derived from the chemical name Bcr-Abl Fusion Enzyme Tyrosine kINase InhiBitor. The name reflects its function as a tyrosine kinase inhibitor, which blocks the action of enzymes known as tyrosine kinases, thus preventing the growth and division of cancer cells.
Usage
Bafetinib is primarily used in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), particularly in cases where the disease has become resistant to first-line treatment options. It works by blocking the action of the abnormal protein that signals cancer cells to multiply, helping to stop or slow the spread of cancer.
Related Terms
- Protein kinase inhibitor: A type of drug that blocks the action of one or more protein kinases.
- Tyrosine kinase inhibitor: A subclass of protein kinase inhibitors that specifically block the action of tyrosine kinases.
- Chronic myeloid leukemia: A type of cancer that starts in certain blood-forming cells of the bone marrow.
- Acute lymphoblastic leukemia: A type of cancer of the blood and bone marrow that affects white blood cells.
See Also
External links
- Medical encyclopedia article on Bafetinib
- Wikipedia's article - Bafetinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski